Search research articles
Contact Us
Filters
Showing results (141-150 of 179) with videos related to
Page
of 18
Sort By:
Cancer Immunology, Immunotherapy : CII
|
January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
Pedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
The New England Journal of Medicine
|
October 17, 2025
Sevabertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
Xiuning Le, Tae Min Kim, Herbert H Loong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Federica Pecci, Hui Li, Alessandro Di Federico, et al.
Cancer Cell
|
July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve <i>EGFR</i>-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)
Xiuning Le, Jyoti D Patel, Elaine Shum, et al.
Journal for Immunotherapy of Cancer
|
July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
Mehmet Altan, Yan Wang, Juhee Song, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 18, 2026
Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs
Monique B Nilsson, Xiuning Le, Alissa Poteete, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study
Lingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.
Cancer Letters
|
June 18, 2026
Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center Study
Amgad Muneer, Eman Showkatian, Maliazurina B Saad, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 179) with videos related to
Sort By:
Page
of 18
Cancer Immunology, Immunotherapy : CII
|
January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
Pedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
The New England Journal of Medicine
|
October 17, 2025
Sevabertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
Xiuning Le, Tae Min Kim, Herbert H Loong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Federica Pecci, Hui Li, Alessandro Di Federico, et al.
Cancer Cell
|
July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve <i>EGFR</i>-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)
Xiuning Le, Jyoti D Patel, Elaine Shum, et al.
Journal for Immunotherapy of Cancer
|
July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
Mehmet Altan, Yan Wang, Juhee Song, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 18, 2026
Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs
Monique B Nilsson, Xiuning Le, Alissa Poteete, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study
Lingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.
Cancer Letters
|
June 18, 2026
Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center Study
Amgad Muneer, Eman Showkatian, Maliazurina B Saad, et al.
Page
of 18